Exicure, Inc. Announces Resignation of Board Member Sangjin Yeo

Key Developments

• Director Resignation: Exicure, Inc. announced that on March 25, 2026, Sangjin Yeo submitted his resignation from the company’s Board of Directors and the Audit Committee, with the resignation effective as of March 27, 2026.
• No Disagreement with Company: The company clarified that Mr. Yeo’s resignation was not due to any disagreement with Exicure, Inc. regarding its operations, policies, or practices.

Details for Investors

Exicure, Inc. (NASDAQ: XCUR), a pharmaceutical company incorporated in Delaware and headquartered at 400 Seaport Court, Suite 102, Redwood City, CA 94063, reported a significant change in its governance. The company’s common stock trades under the symbol XCUR on the NASDAQ Stock Market.

• Board and Audit Committee Impact: The departure of Mr. Yeo from the Board of Directors and the Audit Committee could have implications for the company’s governance structure and oversight, particularly as the audit committee plays a critical role in financial reporting and compliance.
• Potential Shareholder Implications: While the company explicitly stated that there were no disagreements or disputes leading to the resignation, any change in board composition—especially involving the audit committee—can be considered material and potentially price-sensitive information. Investors often react to such changes, as they may signal shifts in company oversight or future strategic direction.

Background on Company

• Incorporation and Registration: Exicure, Inc. is incorporated in Delaware (EIN: 81-5333008) and is registered with the SEC under file number 001-39011.
• Business Focus: The company is classified under pharmaceutical preparations (SIC Code: 2834).
• Contact: For further information, shareholders may contact the company at (847) 673-1700.

Shareholder Considerations

• Potential Share Price Movement: Leadership and board changes, particularly involving audit oversight, are closely monitored by institutional investors and the market as they may precede strategic shifts or signal changes in company governance.
• No Indication of Financial Restatement or Disagreement: The disclosure explicitly notes the resignation was not due to any disagreement with company policies or practices, which may alleviate some investor concerns regarding financial integrity or internal conflict.
• Ongoing Compliance: The company’s 8-K filing confirms ongoing compliance with SEC requirements and transparent disclosure of material events.

Management Statement

The report was signed by Jung Soo Kim, Chief Executive Officer, on behalf of Exicure, Inc., dated March 27, 2026.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions based on board or management changes. The information presented herein is based on the company’s public SEC filing as of March 27, 2026.

View EXICURE, INC. Historical chart here